Home/Pipeline/FAP-2286 (Therapeutic)

FAP-2286 (Therapeutic)

Various epithelial cancers (pan-tumor)

Phase 1/2Active

Key Facts

Indication
Various epithelial cancers (pan-tumor)
Phase
Phase 1/2
Status
Active
Company

About 3B Pharmaceuticals

3B Pharmaceuticals is a German biotech specializing in targeted radiopharmaceuticals for cancer diagnosis and therapy. The company has built a diversified pipeline targeting pan-tumor antigens like FAP, as well as NTR1, CAIX, and GIP receptors, with key assets partnered with major players like Novartis and Debiopharm. Operating as a private, R&D-focused entity, 3B leverages its proprietary platform to develop novel radioligands, positioning itself in the rapidly growing field of precision oncology and theranostics.

View full company profile

Therapeutic Areas